Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Merck KGaA
  6. News
  7. Summary
    MRK   DE0006599905


Real-time Estimate Quote. Real-time Estimate Tradegate - 10/22 03:59:09 pm
203.05 EUR   -0.17%
12:42aMERCK : Moody's Raises Merck KGaA's Rating to A3 on Improved Business Profile
10/21MARKETMIND : Back to the blues
10/20MERCK KGAA : Barclays takes a positive view
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : Darmstadt, Germany, and Three Partners Start ExploreBio, a € 20 million Pre-seed Investment Initiative in Israel

02/20/2018 | 06:11am EDT
  • Arkin Holdings, Pontifax and WuXi AppTec partner with strategic corporate venture capital arm of Merck KGaA, Darmstadt, Germany
  • Overall volume of € 20 million for five years
  • Merck KGaA, Darmstadt, Germany, also announces CRISPR-patent allowances in Israel and South Korea

Darmstadt, Germany, February 20, 2018 - Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced ExploreBio, a pre-seed-investment vehicle by four investment funds targeted at early-stage companies in the biotechnology landscape in Israel. For this purpose the strategic corporate venture capital arm of Merck KGaA, Darmstadt, Germany has partnered with Arkin Holdings, Pontifax and WuXi AppTec to create the € 20 million pre-seed investment vehicle.

'Israel's start-up spirit is unique and so inspiring. We are proud to be an active part of this great success story. Now we are taking a next important investment step as we believe in the innovative potential of ExploreBio,' said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany.

ExploreBio is an initiative comprising pre-seed investments and management services for proof-of-concept-experiments in biotechnology. Additionally, companies benefiting from the ExploreBio initiative will be given the opportunity to work at the BioIncubator facilities of Merck KGaA, Darmstadt, Germany, in Yavne, Israel. Interested parties should submit their investment proposal here.

The commitment involves a total volume of € 20 million for five years. ExploreBio aims to invest € 1 million to € 1.5 million per company across up to four investments per year over a period of five years. The early-stage companies would benefit from quick access to funding and easy access to follow-up capital.

The four investors have worked together on investments in different companies in the past, such as Metabomed (targeted cancer therapy) and Artsavit (using apoptosis-induction to treat cancer).

With the new ExploreBio initiative, Merck KGaA, Darmstadt, Germany, and its three partners aim to engage with start-up companies in which it would otherwise be too early to invest. A second advantage for the four partners is being able to leverage the consortium's resources and their strong relationships to work with the investments more closely and effectively.

ExploreBio complements the activities of Merck KGaA, Darmstadt, Germany, in helping early-stage companies in Israel to mature. The company set up PMatX last year and has been running its BioIncubator in Yavne since 2011.

PMatX addresses the topic of next-generation electronics and is a joint endeavor with Flex, San Jose, California, USA, and also backed by additional industry partners including HP, Palo Alto, California, USA, and the U.S.- based global investment firm Battery Ventures. PMAtX is supported by the Technology Innovation Lab program of the Israel Innovation Authority (IIA). The overall investment volume of the program involving all parties is around € 20 million and the initial commitment is for three years.

The site of Merck KGaA, Darmstadt, Germany, in Yavne houses the company's Healthcare and Life Science incubator called BioIncubator. This successful undertaking was started in 2011 and has committed to invest up to € 10 million until 2018 in biomedically focused start-up companies in Israel.

Merck KGaA, Darmstadt, Germany, employs more than 300 people in Israel, mainly scientists, and has sites in Yavne, Herziliya, Rehovot, and Jerusalem. All three of its business sectors, Healthcare, Life Science and Performance Materials, have R&D sites in Israel.

The company also announces today that the Israel Patent Office as well as the Korean Intellectual Property Office have each issued notices granting patent applications of Merck KGaA, Darmstadt, Germany, for its CRISPR technology used in a genomic-integration method for eukaryotic cells. These decisions mark the fifth and sixth patent allowances for the unique CRISPR technology of Merck KGaA, Darmstadt, Germany, following Singapore, Australia, the European Union, and Canada. Merck KGaA, Darmstadt, Germany, also has patent filings for its insertion CRISPR method in the United States, Brazil, China, India, and Japan.

Merck KGaA published this content on 20 February 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 20 February 2018 11:10:06 UTC.

© Publicnow 2018
All news about MERCK KGAA
12:42aMERCK : Moody's Raises Merck KGaA's Rating to A3 on Improved Business Profile
10/21MARKETMIND : Back to the blues
10/20MERCK KGAA : Barclays takes a positive view
10/20CytoReason Collaborates with Merck KGaA on Cancer Immunotherapy Drug
10/20MARKETMIND : Margin pressures
10/19MARKETMIND : Fast and furious
10/14MERCK KGAA : Release according to Article 40, Section 1 of the WpHG [the German Securities..
10/14MERCK : EMD Serono, Inc. - New Real-World MAVENCLAD Data Show Sustained Effectiveness and ..
10/13Merck KGaA's Multiple Sclerosis Treatment Drug Shows Improved Quality Of Life In Study
10/13MERCK KGAA : JP Morgan reaffirms its Buy rating
More news
Analyst Recommendations on MERCK KGAA
More recommendations
Sales 2021 19 375 M 22 566 M 22 566 M
Net income 2021 2 765 M 3 221 M 3 221 M
Net Debt 2021 8 932 M 10 403 M 10 403 M
P/E ratio 2021 31,5x
Yield 2021 0,76%
Capitalization 87 999 M 102 B 102 B
EV / Sales 2021 5,00x
EV / Sales 2022 4,59x
Nbr of Employees 58 408
Free-Float 29,7%
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 202,40 €
Average target price 200,03 €
Spread / Average Target -1,17%
EPS Revisions
Managers and Directors
Belén Garijo López Chairman-Executive Board & CEO
Marcus Kuhnert Chief Financial Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Maria Rivas Chief Medical Officer & Senior Vice President
Laura Matz Chief Science & Technology Officer
Sector and Competitors